STAAR Surgical Company(STAA)今日盘中大涨5.24%，引起了市场的广泛关注。
消息面上，该公司于前一日盘后公布的2026年第一季度初步业绩指引大幅超出市场预期，预计净销售额将超过9000万美元，较2025年同期增长逾一倍，远超分析师此前预期。此外，STAAR Surgical在中国市场的库存已恢复正常范围，供货全面恢复，同时新一代产品EVO+ ICL（V5）已在中国正式上市，这些积极因素共同推动了股价的上涨。
多家机构也因此上调了对该公司的评级和目标价，进一步增强了市场信心。STAAR Surgical作为全球植入式隐形眼镜市场的领导者，正从之前的低谷中重拾增长动能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.